Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability
I said, You know what
These forces intensify during menopause, when shifting hormones drive stubborn weight gain around the midsection that diet and exercise alone rarely resolve
When you schedule your free consultation, your treatment specialist will walk you through any first-time promotions, limited-time offers, bundles, and packages available
10.1126/scitranslmed.3007218 Summary Keywords gut hormones, bone metabolism, GIP, GLP-1, GLP-2, PYY, osteoporosis Citation Schiellerup SP, Skov-Jeppesen K, Windelv JA, Svane MS, Holst JJ, Hartmann B and Rosenkilde MM (2019) Gut Hormones and Their Effect on Bone Metabolism
Its best to discuss the risks and benefits with your healthcare provider
